As a result of our CSR initiatives, we actively contribute to will cause that align with our values and mission.In March of 2019, the S(+) stereoisomer of ketamine termed esketamine was approved via the FDA as a quick-acting antidepressant. It relieves the indicators of despair in just four hours of use and these effects can last for so long as var… Read More